CAJ | 학술논문

目的比较速效胰岛素类似物( 诺和锐)和短效人胰岛素(诺和灵R)用外置的胰岛素泵持续皮下输注(CSⅡ)治疗2型糖尿病(T2DM)的疗效. 方法该研究为持续24周随机、开放、交叉实验,29例T2DM患者,随机分为诺和锐组和诺和灵R组,诺和锐为餐前即刻输注,诺和灵R为餐前30 min输注,12周治疗后两组交换用药.观察两种不同治疗方式患者糖化血红蛋白(HbA1c)、8个时点(3餐前后、睡前、凌晨2点)血糖、低血糖及胰岛素泵的安全性的差异. 结果接受诺和锐治疗组的患者HbA1c指标好于诺和灵R组(P<0.01).8个时点血糖检测显示诺和锐组三餐后及睡前血糖水平均低于诺和灵R组(P<0.01～0.05).两组患者胰岛素用量、低血糖发生率及胰岛素泵的安全性均无差异. 结论诺和锐与诺和灵R均可安全有效的降低血糖及HbA1c,诺和锐用于CSⅡ控制餐后血糖更具优点.
목적 비교속효이도소유사물( 낙화예)화단효인이도소(낙화령R)용외치적이도소빙지속피하수주(CSⅡ)치료2형당뇨병(T2DM)적료효. 방법해연구위지속24주수궤、개방、교차실험,29례T2DM환자,수궤분위낙화예조화낙화령R조,낙화예위찬전즉각수주,낙화령R위찬전30 min수주,12주치료후량조교환용약.관찰량충불동치료방식환자당화혈홍단백(HbA1c)、8개시점(3찬전후、수전、릉신2점)혈당、저혈당급이도소빙적안전성적차이. 결과접수낙화예치료조적환자HbA1c지표호우낙화령R조(P<0.01).8개시점혈당검측현시낙화예조삼찬후급수전혈당수평균저우낙화령R조(P<0.01～0.05).량조환자이도소용량、저혈당발생솔급이도소빙적안전성균무차이. 결론낙화예여낙화령R균가안전유효적강저혈당급HbA1c,낙화예용우CSⅡ공제찬후혈당경구우점.
Objective To compare the safety and efficiency between insulin aspart(IAsp) and human regular insulin(HRI) in elderly patients with type 2 diabetes via continuous subcutaneous insulin infusion (CSII) pump Methods In the 24 weeks of randomized, opened and crossed trial, 29 patients on CSII with adequate blood glucose control received either IAsp or HRI for 12 weeks, followed by the two groups of patients exchanging the two drugs for another 12 weeks Bolus HRI doses were administered 30 min before meals and Iasp immediately before meals Efficacy and safety measures included hemoglobin A1c (HbA 1c) at baseline and endpoint, eight point(before and after three meals, at bedtime and 2AM)blood glucose profiles, and frequency of hypoglycemia and pump catheter occlusion Results Insulin aspart was associated with a significantly lower HbA 1c than human regular insulin( P <0 01) Fasting or 2AM serum glucose levels were similar between the two therapies The glucose concentrations at three postprandial or bedtime were significantly lower during treatments with insulin aspart( P <0 01 or P <0 05) No differences between the two treatments were observed in basal or bolus insulin dosages and the incidence of hypoglycemia and pump occlusions Conclusions Insulin aspart in CSII is as efficacious and well tolerated as HRI, but insulin aspart provides better postprandial glucose control than human regular insulin